330 related articles for article (PubMed ID: 17637782)
1. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
2. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
5. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
6. A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Etienne-Grimaldi MC; François E; Cardot JM; Renée N; Douillard JY; Gamelin E; Bennouna J; Château Y; Milano G
Clin Pharmacokinet; 2007; 46(11):953-63. PubMed ID: 17922560
[TBL] [Abstract][Full Text] [Related]
7. [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
Tomita M; Shimoyama T; Hirano T; Nakagoe T; Shimizu T; Kusano H; Fukuda Y; Eida K; Ishii T; Kotake Y
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3239-43. PubMed ID: 3143310
[TBL] [Abstract][Full Text] [Related]
8. [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Inaba S; Kondo Y; Tsuchiya K; Kawai K; Ogino A; Umeda T; Ueda Y
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2175-80. PubMed ID: 1444483
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Sakamoto K; Arita S; Hisikawa E; Yaguchi H; Arima H; Matsumoto M; Hachisu T; Kashiwabara H; Yokoyama T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):239-44. PubMed ID: 7857099
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
12. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
[TBL] [Abstract][Full Text] [Related]
13. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
14. Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats.
Kobuchi S; Ito Y; Takamatsu D; Sakaeda T
Eur J Pharm Sci; 2018 Oct; 123():452-458. PubMed ID: 30077713
[TBL] [Abstract][Full Text] [Related]
15. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
16. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
[TBL] [Abstract][Full Text] [Related]
17. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
